Infliximab for pediatric patients with ulcerative colitis: A phase 3, open-label, uncontrolled, multicenter trial in Japan

Pediatric ulcerative colitis (UC) is typically more extensive and has a more active disease course than adult UC, and requires early treatment augmentation to achieve and maintain disease remission.